Drugs /
cd33 car t-cells
Overview
Clinical Trials
Cd33 car t-cells has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating cd33 car t-cells, 1 is phase 1/phase 2 (1 open).
CD33 Expression is the most frequent biomarker inclusion criterion for cd33 car t-cells clinical trials.
Acute myeloid leukemia is the most common disease being investigated in cd33 car t-cells clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.